ImmuneOncia Therapeutics (A424870) Stock Overview
An immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A424870 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ImmuneOncia Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,580.00 |
| 52 Week High | ₩12,100.00 |
| 52 Week Low | ₩4,455.00 |
| Beta | 0 |
| 1 Month Change | 108.65% |
| 3 Month Change | 101.39% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 54.40% |
Recent News & Updates
Companies Like ImmuneOncia Therapeutics (KOSDAQ:424870) Are In A Position To Invest In Growth
Dec 08
We Think ImmuneOncia Therapeutics (KOSDAQ:424870) Needs To Drive Business Growth Carefully
Aug 22Shareholder Returns
| A424870 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 13.0% | -0.9% | 3.3% |
| 1Y | n/a | 47.4% | 67.7% |
Return vs Industry: Insufficient data to determine how A424870 performed against the KR Biotechs industry.
Return vs Market: Insufficient data to determine how A424870 performed against the KR Market.
Price Volatility
| A424870 volatility | |
|---|---|
| A424870 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A424870's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A424870's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Heung Tae Kim | www.immuneoncia.com |
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy.
ImmuneOncia Therapeutics, Inc. Fundamentals Summary
| A424870 fundamental statistics | |
|---|---|
| Market cap | ₩858.83b |
| Earnings (TTM) | -₩20.52b |
| Revenue (TTM) | ₩715.75m |
Is A424870 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A424870 income statement (TTM) | |
|---|---|
| Revenue | ₩715.75m |
| Cost of Revenue | ₩12.56m |
| Gross Profit | ₩703.19m |
| Other Expenses | ₩21.22b |
| Earnings | -₩20.52b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -276.68 |
| Gross Margin | 98.25% |
| Net Profit Margin | -2,866.97% |
| Debt/Equity Ratio | 0% |
How did A424870 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 23:19 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuneOncia Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.